GT Biopharma (GTBP) Receivables (2013 - 2014)

GT Biopharma (GTBP) posted quarterly Receivables of $5000.0 for Q2 2014, down 83.33% quarter-over-quarter from $30000.0 in Q1 2014.

GT Biopharma (GTBP) Receivables (2013 - 2014) Analysis & Trends

GT Biopharma (GTBP) has reported Receivables for 2 consecutive years, with $5000.0 the latest figure, recorded in Q2 2014.

In Q2 2014, Receivables changed N/A year-over-year to $5000.0; the TTM figure through Jun 2014 stood at $5000.0 (changed N/A YoY), while the FY2013 annual figure was $40000.0, changed N/A from the prior year.
Receivables eased to $5000.0 in Q2 2014 per GTBP's latest filing, from $30000.0 in the prior quarter.
Across five years, Receivables topped out at $40000.0 in Q4 2013 and bottomed at $5000.0 in Q2 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.93 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	912.74 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	215.33 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.09 Bn
10	GT Biopharma	8.38 Mn	8.38 Mn	-	-

Download Data